Thermo Fisher Scientific Inc (NYSE:TMO) – Research analysts at Leerink Swann cut their Q4 2017 EPS estimates for shares of Thermo Fisher Scientific in a note issued to investors on Thursday, according to Zacks Investment Research. Leerink Swann analyst P. Souda now anticipates that the medical research company will earn $2.65 per share for the quarter, down from their previous forecast of $2.68. Leerink Swann has a “Buy” rating on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q1 2018 earnings at $2.37 EPS, Q4 2018 earnings at $2.86 EPS, FY2018 earnings at $10.44 EPS and Q1 2019 earnings at $2.65 EPS.
TMO has been the subject of a number of other reports. Jefferies Group LLC restated a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a research note on Thursday, September 7th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $205.71.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/equities-analysts-issue-forecasts-for-thermo-fisher-scientific-incs-q4-2017-earnings-tmo.html.
Thermo Fisher Scientific (NYSE TMO) traded down $5.71 during trading hours on Friday, reaching $186.18. 3,009,200 shares of the company’s stock were exchanged, compared to its average volume of 1,551,175. The company has a market cap of $76,947.01, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.76 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific has a 1-year low of $139.07 and a 1-year high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. Thermo Fisher Scientific’s revenue was up 13.9% compared to the same quarter last year. During the same period last year, the business earned $2.03 EPS.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.
In related news, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $177.80, for a total value of $736,092.00. Following the transaction, the vice president now owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last three months, insiders sold 22,738 shares of company stock worth $4,021,512. 0.49% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 2,692.1% during the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares during the period. Capital Research Global Investors raised its stake in Thermo Fisher Scientific by 29.8% during the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares during the period. Janus Henderson Group PLC raised its stake in Thermo Fisher Scientific by 2,058.1% during the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares during the period. Veritas Asset Management LLP raised its stake in Thermo Fisher Scientific by 112.4% during the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares during the period. Finally, Harbour Capital Advisors LLC raised its stake in Thermo Fisher Scientific by 18,197.5% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after acquiring an additional 1,194,487 shares during the period. Institutional investors own 83.66% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.